8-K: Amgen Reports Strong Q4 and Full Year 2023 Results Driven by Volume Growth and Horizon Acquisition

Amgen's fourth quarter and full year 2023 results show significant revenue growth, driven by volume increases and the acquisition of Horizon Therapeutics.

Summary

• Amgen's total revenue for the fourth quarter of 2023 increased by 20% to $8.2 billion compared to the same period in 2022.
• Product sales grew by 20% in the fourth quarter, with a 23% increase in volume, partially offset by a 3% decrease in net selling price.
• Nine brands achieved record sales in the fourth quarter, with Repatha, EVENITY, Prolia, and BLINCYTO showing double-digit volume growth globally.
• The acquisition of Horizon Therapeutics contributed $954 million in sales from October 6 to December 31, 2023.
• For the full year 2023, total revenue increased by 7% to $28.2 billion, with product sales up by 9%.
• Full year product sales growth was driven by a 15% increase in volume, partially offset by a 3% decrease in net selling price, a 1% unfavorable change from estimated sales deductions, and a 1% negative impact from foreign exchange.
• GAAP earnings per share (EPS) decreased by 53% in the fourth quarter to $1.42, while full year GAAP EPS increased by 3% to $12.49.
• Non-GAAP EPS increased by 15% to $4.71 in the fourth quarter and by 5% to $18.65 for the full year.
• The company generated $7.4 billion in free cash flow for the full year, compared to $8.8 billion in 2022.
• Amgen expects total revenue between $32.4 billion and $33.8 billion for 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, successful acquisition integration, and promising pipeline developments. However, the decrease in GAAP EPS and free cash flow, along with some price erosion, temper the overall sentiment slightly.

Positives

• Strong revenue growth driven by volume increases and the Horizon acquisition.
• Double-digit volume growth for key products like Repatha, EVENITY, Prolia, and BLINCYTO.
• Successful integration of Horizon Therapeutics, contributing significantly to revenue.
• Positive non-GAAP EPS growth for both the quarter and the full year.
• Anticipated pipeline milestones in 2024 suggest future growth potential.
• The company has provided positive revenue guidance for 2024.

Negatives

• GAAP EPS decreased significantly in the fourth quarter due to acquisition-related expenses and incremental operating expenses from Horizon.
• Free cash flow decreased in 2023 due to transaction expenses related to the Horizon acquisition and higher repatriation tax payments.
• GAAP operating margin decreased significantly in both the fourth quarter and full year.
• Some products experienced price erosion, impacting overall revenue growth.
• The company expects lower sales for Otezla and Enbrel in the first quarter due to benefit plan changes.

Risks

• The company faces pricing pressure and competition from biosimilars.
• Regulatory and clinical developments could impact product sales.
• The company is subject to extensive regulation by domestic and foreign government regulatory authorities.
• There are risks associated with manufacturing and supply chain.
• The company's business may be impacted by government investigations, litigation, and product liability claims.
• The company may not be able to realize the strategic benefits of the Horizon acquisition.
• The company's stock price is volatile and may be affected by a number of events.
• Global economic conditions may magnify certain risks that affect the business.

Future Outlook

Amgen expects total revenues in the range of $32.4 billion to $33.8 billion for the full year 2024. They also anticipate GAAP EPS between $8.42 and $9.87 and non-GAAP EPS between $18.90 and $20.30. Capital expenditures are expected to be approximately $1.1 billion, and share repurchases are not to exceed $500 million.

Management Comments

• Robert A. Bradway, chairman and chief executive officer, stated that 2023 was another year of performance and progress for the company.
• He also mentioned that their marketed products are reaching many more patients around the world, and they anticipate more than a dozen significant pipeline milestones in 2024.

Industry Context

Amgen's results reflect the ongoing trend of pharmaceutical companies focusing on volume growth and strategic acquisitions to drive revenue. The acquisition of Horizon Therapeutics is a significant move to expand their portfolio in rare diseases. The company's focus on pipeline development and regulatory approvals is also consistent with industry trends.

Comparison to Industry Standards

• Amgen's 20% revenue growth in Q4 is strong compared to the average growth of large-cap pharmaceutical companies, which typically see single-digit growth.
• The 23% volume growth in Q4 is particularly impressive, indicating strong demand for their products.
• The acquisition of Horizon Therapeutics is similar to other large pharmaceutical companies acquiring smaller biotech firms to expand their product portfolios, such as Pfizer's acquisition of Biohaven.
• Amgen's focus on biosimilars is in line with the industry trend of developing lower-cost alternatives to branded drugs, similar to companies like Sandoz and Teva.
• The company's pipeline development, including the priority review for tarlatamab and BLINCYTO, is comparable to other companies with strong R&D programs, such as Regeneron and AbbVie.

Stakeholder Impact

• Shareholders will likely react positively to the strong revenue growth and non-GAAP EPS performance.
• Employees may benefit from the company's growth and expansion.
• Customers will have access to a broader range of innovative therapies.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company's financial performance favorably.

Next Steps

• The company plans to continue enrolling patients in various clinical trials.
• They anticipate topline data from the Phase 2 study of maridebart cafraglutide in late 2024.
• They plan to initiate a Phase 3 study of TEPEZZA with subcutaneous administration in H1 2024.
• A U.S. regulatory submission is planned for the Phase 3 CodeBreaK 300 trial in H1 2024.
• The company is planning to amend the Golden Gate Phase 3 study to include an evaluation of blinatumomab subcutaneous administration with initiation anticipated in H2 2024.

Key Dates

Keywords

Amgen, Financial Results, Horizon Therapeutics, Revenue Growth, Product Sales, Earnings Per Share, Non-GAAP, Free Cash Flow, Acquisition, Pharmaceuticals, Biotechnology